Earlier this month Copenhagen-based Cerebriu, who provides an AI-powered solution that optimizes MRI workflows, announced they raised € 17.4 million in a Series A funding round. The round was led by North Ventures, with continued support from EIFO and Sagitta Ventures. The funding will accelerate the expansion of Cerebriu’s Apollo software, improving efficiency and reducing patient wait times, and the company’s global growth.
CEO Robert Lauritzen highlighted that the investment would help address the rising demand for MRI exams amid global radiologist shortages.
“We are thrilled to announce closing our Series A Round, which will enable us to further deploy our Software Suite Apollo to address the growing gap between the need for MRI exams and the foreseen shortage of radiologists and radiographers. With the support of our investors, we can continue to innovate and develop Cerebriu’s AI product line to improve MRI accessibility worldwide.”
he said
Apollo, already implemented in hospitals across Europe, Asia, and the Middle East, works as a clinical companion for MRI technologists, optimizing scan times and reducing unnecessary patient recalls. Cerebriu is also partnering with Siemens Healthineers and leading hospitals in the USA for further clinical validation.
Mikkel Rørvig, Partner at North Ventures, is confident in Cerebriu’s potential to transform healthcare, noting that the company’s AI solutions will play a crucial role in enhancing radiology workflows worldwide. The funding will also allow Cerebriu to expand its product portfolio and accelerate commercial growth, aiming to make MRI technology more accessible and efficient on a global scale.
“Their AI-powered solutions are poised to play a crucial role in improving radiology workflows and enhancing the overall quality of care in healthcare systems worldwide. We’re proud to support their growth.”
Mikkel said
Cerebriu’s aim is to address critical challenges in healthcare by using AI to support radiology departments dealing with rising imaging demands and staffing shortages. With this latest investment, the company is well-positioned to make a significant impact on improving patient outcomes and enhancing the quality of healthcare across the globe.
